On the efficiency of treatment of wet age-related macular degeneration with Lucentis
The paper studies the efficiency of ranibizumab (Lucentis, Novartis Pharma), a VEGF blocker inhibiting angiogenesis, in patients with wet age macular degeneration (AMD) at different stages of the pathological process. The research included 21 patients (30 eyes), averagely aged 65.1 ± 1.3 years. Intr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2018-10-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/23 |
| Summary: | The paper studies the efficiency of ranibizumab (Lucentis, Novartis Pharma), a VEGF blocker inhibiting angiogenesis, in patients with wet age macular degeneration (AMD) at different stages of the pathological process. The research included 21 patients (30 eyes), averagely aged 65.1 ± 1.3 years. Intravitreal administration of the medication contributed to a reliable increase of vision acuity and a reliable decrease of pigment epithelium detachment in patients with wet AMD at the stage of prechoroidal neovascularization, pigment epithelium detachment and subretinal neovascular membrane and, in a lesser degree, at the stage of macular fibrosis // Russian Ophthalmological Journal, 2016; 2: 33-37 . doi: 10.21516/2072-0076-2016-9-2-33-37 . |
|---|---|
| ISSN: | 2072-0076 2587-5760 |